Telomir Pharmaceuticals, Inc. TELO
0.89 USD -0.02 (-2.41%)
Nov 4, 2026, 1:54 PM EST
0.8601 Day range 0.93
0.791 52-week range 1.58
- YTD
- -33.23%
- 1 year
- -37.01%
Financial health
Altman Z-Score
107.02 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -4.0×
FY 2021 5y median -15.9× FY 2025
P/S 0.0×
FY 2021 5y median 0.0× FY 2025
P/B 7.1×
FY 2021 5y median 7.1× FY 2025
P/FCF -11.4×
FY 2021 5y median -53.7× FY 2025
EV/EBITDA -3.4×
FY 2021 5y median -3.4× FY 2025
EV/Sales 0.0×
FY 2021 5y median 0.0× FY 2025
FCF Yield -8.8%
FY 2021 5y median -1.9% FY 2025
Profitability
Gross Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2021 5y median 0.0% FY 2025
ROE -176.1%
FY 2021 5y median -176.1% FY 2025
ROIC -165.0%
FY 2021 5y median -165.0% FY 2025
ROA -141.8%
FY 2021 5y median -273.8% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2021 FY 2025
Operating Income 13.9%
FY 2021 FY 2025
EPS (diluted) 41.1%
FY 2021 FY 2025
Free Cash Flow 27.3%
FY 2021 FY 2025
Financial Health
Current Ratio 5.1×
FY 2021 5y median 0.3× FY 2025
Quick Ratio 5.1×
FY 2021 5y median 0.3× FY 2025
Debt / Equity 0.1×
FY 2021 5y median 0.0× FY 2025
Net Debt / EBITDA 0.7×
FY 2021 5y median 0.0× FY 2025
Interest Coverage 0.0×
FY 2021 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31